Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
77.84
+0.86 (+1.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
99
100
Next >
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
May 24, 2024
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with...
Via
Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
May 24, 2024
The company passed investors' bar for success in a study of a head-and-neck cancer treatment.
Via
Investor's Business Daily
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
May 24, 2024
The billionaire hedge fund manager doesn't need dividend income. But he'll get more of it after his Q1 purchases.
Via
The Motley Fool
Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day
May 23, 2024
Summer has arrived on Wall Street! Discover three cheap stocks to buy with solid fundamentals to boost your profitability this season.
Via
InvestorPlace
MERCK & CO. INC. (NYSE:MRK) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
May 23, 2024
Exploring MERCK & CO. INC.'s Technical Signals and Breakout Potential.
Via
Chartmill
Performance Comparison: Merck & Co And Competitors In Pharmaceuticals Industry
May 21, 2024
Via
Benzinga
Check Out What Whales Are Doing With MRK
May 16, 2024
Via
Benzinga
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
May 07, 2024
Via
Benzinga
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
5 Stocks Powering The Dow ETF Year To Date
May 17, 2024
While most of the stocks in the ETF portfolio have been rising this year, these five that have been leading the way higher.
Via
Talk Markets
Topics
ETFs
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
May 17, 2024
Via
Benzinga
Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches
May 17, 2024
With the market potentially posing some challenges, investors may find comfort in considering these safe haven stocks to buy.
Via
InvestorPlace
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
May 16, 2024
It depends on what your goals, objectives, and risk tolerances are.
Via
Talk Markets
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 15, 2024
Via
Benzinga
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
May 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
May 13, 2024
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.
Via
Benzinga
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
May 13, 2024
From
Merck & Co., Inc.
Via
Business Wire
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
May 10, 2024
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy.
Via
Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
May 10, 2024
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
Via
InvestorPlace
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
May 10, 2024
These are the undervalued healthcare stocks to buy as they represent companies with steady growth visibility.
Via
InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
May 09, 2024
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.
Via
InvestorPlace
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
May 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
May 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
May 08, 2024
Jim Cramer, the host of CNBC's "Mad Money," has warned investors about the current state of the economy and suggested strategies to navigate the challenging period.
Via
Benzinga
Topics
Economy
Exposures
Economy
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 08, 2024
From
FN Media Group LLC
Via
GlobeNewswire
A Look At Pharma ETFs Post Q1 Earnings
May 07, 2024
Pharma ETFs have delivered mixed performances over the past month.
Via
Talk Markets
Topics
ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
May 07, 2024
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.